2019
An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study
Romano M, Parolini B, Allegrini D, Michalewska Z, Adelman R, Bonovas S, Bopp S, group E. An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study. Acta Ophthalmologica 2019, 98: e549-e558. PMID: 31808315, DOI: 10.1111/aos.14319.Peer-Reviewed Original ResearchBest-corrected visual acuityCentral serous chorioretinopathyOdds ratioLaser photocoagulationTherapeutic optionsComplete resolutionUnivariate analysisAnatomical resultsAntivascular endothelial growth factor injectionsNonsteroidal anti-inflammatory eye dropsTreatment of central serous chorioretinopathyComplete resolution of fluidDuration of observationMicropulse diode laser photocoagulationAnti-inflammatory eye dropsDiode laser photocoagulationPars plana vitrectomyGrowth factor injectionsResolution of fluidMonths of treatmentPercentage of patientsInternational multicentre studyMethod of treatmentStatistically significant differenceAnti-anxiety drugs
2013
Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
Karim SP, Adelman RA. Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy. Clinical Ophthalmology 2013, Volume 7: 1867-1875. PMID: 24092965, PMCID: PMC3788817, DOI: 10.2147/opth.s32177.Peer-Reviewed Original ResearchCentral serous chorioretinopathySerous chorioretinopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsSafety of PDTTreatment of CSCRPhotodynamic therapyChronic recurrent formGrowth factor agentsPermanent visual lossPossible pathophysiologic mechanismsSerous retinal detachmentProspective interventional studyLong-term efficacyPigment epithelial detachmentPotential therapeutic optionEfficacy of PDTMajority of casesFactor agentsAnatomic improvementFoveal atrophyPigment epitheliopathyRetinal detachmentVisual lossFluorescein angiography
2011
The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab
Lee ST, Adelman RA. The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab. Journal Of Ocular Pharmacology And Therapeutics 2011, 27: 611-614. PMID: 21810026, DOI: 10.1089/jop.2011.0045.Peer-Reviewed Original ResearchConceptsRecurrent central serous chorioretinopathyMean central macular thicknessCentral macular thicknessCentral serous chorioretinopathyPreinjection visual acuityVisual acuityOptical coherence tomographyIntravitreal bevacizumabSerous chorioretinopathyTreatment optionsLow-risk treatment optionYale Eye CenterIntravitreal bevacizumab injectionRetrospective case seriesEffective treatment optionLong-term efficacySub-retinal fluidNumber of injectionsFluorescein angiography imagingBevacizumab injectionRecurrent diseaseMacular thicknessMonth 3Month 6Case series